Dare Bioscience Inc expected to post a loss of 73 cents a share - Earnings Preview

Dare Bioscience

06/11/2024 14:01

* Dare Bioscience Inc  DARE.OQ   DARE.O  is expected to show
a
rise in quarterly revenue when it reports  results on November 7
(estimated) for the period ending September 30 2024
    * The San Diego California-based  company is expected to
report a
304.6% increase in revenue to $4.046 million from $1 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Dare Bioscience Inc is
for a
loss of 73 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for
the pharmaceuticals
peer group is also "Buy".​
    * Wall Street's median 12-month price target for Dare
Bioscience
Inc is $13.00​, above​ its last closing price of $3.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.65       0.00       -0.88     Missed  
 Mar. 31 2024  -0.72       -0.72      -0.84     Missed  -16.7
 Jan. 1 0001   -1.60       -1.18      -0.72     Beat    38.8​
 Sep. 30 2023  -1.16       -1.18      -1.08     Beat    8.2
 ​​Jan.        -1.21       -1.18      -1.20     Missed  -1.7
 1 0001                                                 
 Mar. 31 2023  -1.22       -1.20      -1.08     Beat    10​
 Dec. 31 2022  -1.62       -1.64      -2.28     Missed  -39
 Sep. 30 2022  -1.35       -1.41      -0.96     Beat    31.9
 This summary was machine generated November 6 at 14:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)